Investors felt the cannabis executive order didn't go far enough. Tilray's CEO backed President Trump's decision, but called it an "incremental step." 10 stocks we like better than Tilray Brands › It was an exciting week in the cannabis sector.

Shares of cannabis stocks continued their rally Tuesday, after President Donald Trump a day earlier said he was “very strongly” weighing an executive order to reschedule the drug.

Cannabis stocks are set up to complete market reversals that relaxed federal regulations could trigger. Rescheduling isn't legalization, but it's good enough.

Cannabis companies like Tilray Brands and Canopy Growth could soon face a more mellow path ahead following President Donald Trump's move to help reclassify the drug's status.

The cannabis industry has moved from the fringe to the mainstream in just a few years, with legal medical markets growing across the world and ongoing research into new therapeutic uses. On the Australian Securities Exchange (ASX),

The drug is still not legal, but reclassifying cannabis to a Schedule III substance is expected to spark new innovation and investment.

It was another busy week in Washington. We discuss President Trump’s decision to reclassify cannabis as a schedule 3 drug, a revealing news story about the inner workings of the White House, and Congress’s decision to leave town without voting to extend expiring healthcare subsidies.